HC Wainwright & Co. Reiterates Buy on LB Pharmaceuticals, Maintains $45 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.5%

Neg 0% Neu 89.5% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and maintains $45 price target.